How to utilize current guidelines to manage patients with cancer at high risk for heart failure.
Cancer therapy related cardiac dysfunction
Cardio-Oncology
Cardiomyopathy
Guideline directed medical therapy
Heart Failure
Prevention
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
07
06
2024
accepted:
19
08
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
Identifiants
pubmed: 39342407
doi: 10.1186/s40959-024-00259-5
pii: 10.1186/s40959-024-00259-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
63Informations de copyright
© 2024. The Author(s).
Références
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. https://doi.org/10.1056/NEJMoa1910549 .
doi: 10.1056/NEJMoa1910549
pubmed: 32101663
ASCVD Risk Estimator Plus. https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/
Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99. https://doi.org/10.1093/eurheartj/ehab674 .
doi: 10.1093/eurheartj/ehab674
pubmed: 34904661
Armenian SH, Armstrong GT, Aune G, et al. Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention. J Clin Oncol. 2018;36(21):2135–44. https://doi.org/10.1200/jco.2017.76.3920 .
doi: 10.1200/jco.2017.76.3920
pubmed: 29874141
pmcid: 6804893
Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–60. https://doi.org/10.1002/ejhf.1920 .
doi: 10.1002/ejhf.1920
pubmed: 32463967
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876–94. https://doi.org/10.1161/cir.0000000000001062 .
doi: 10.1161/cir.0000000000001062
pubmed: 35363500
Badiyan SN, Puckett LL, Vlacich G, et al. Radiation-Induced Cardiovascular Toxicities. Curr Treat Options Oncol. 2022;23(10):1388–404. https://doi.org/10.1007/s11864-022-01012-9 .
doi: 10.1007/s11864-022-01012-9
pubmed: 36087234
Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721–40. https://doi.org/10.1093/ehjci/jet123 .
doi: 10.1093/ehjci/jet123
pubmed: 23847385
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. https://doi.org/10.1016/j.annonc.2019.10.023 .
doi: 10.1016/j.annonc.2019.10.023
pubmed: 31959335
Mitchell JD, Cehic DA, Morgia M, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society. JACC CardioOncol. 2021;3(3):360–80. https://doi.org/10.1016/j.jaccao.2021.06.003 .
doi: 10.1016/j.jaccao.2021.06.003
pubmed: 34604797
pmcid: 8463721
Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(16):2314–20. https://doi.org/10.1016/j.ejca.2015.07.031 .
doi: 10.1016/j.ejca.2015.07.031
pubmed: 26343314
Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardiooncology. 2019;5:1. https://doi.org/10.1186/s40959-019-0036-7 .
doi: 10.1186/s40959-019-0036-7
pubmed: 32154008
pmcid: 7048095
Swain SMVP. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol. 2004;130:1–7.
doi: 10.1007/s00432-003-0498-7
pubmed: 14564513
Swain SM, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, WAdler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–1332.
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244 .
doi: 10.1093/eurheartj/ehac244
pubmed: 36017568
Van Tine BA, Hirbe AC, Oppelt P, et al. Interim analysis of the phase II study: noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue sarcoma. Clin Cancer Res. 2021. https://doi.org/10.1158/1078-0432.CCR-20-4621 .
doi: 10.1158/1078-0432.CCR-20-4621
pubmed: 34321280
pmcid: 8530953
Macedo AVS, Hajjar LA, Lyon AR, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol. 2019;1(1):68–79. https://doi.org/10.1016/j.jaccao.2019.08.003 .
doi: 10.1016/j.jaccao.2019.08.003
pubmed: 34396164
pmcid: 8352186
Schettini F, Giuliano M, Lambertini M, et al. Anthracyclines strike back: rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer. Cancers (Basel). 2021;13(17). https://doi.org/10.3390/cancers13174421
Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39. https://doi.org/10.1016/j.echo.2014.07.012 .
doi: 10.1016/j.echo.2014.07.012
pubmed: 25172399
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333–465. https://doi.org/10.1093/ehjci/jeac106 .
doi: 10.1093/ehjci/jeac106
pubmed: 36017575
Suero-Abreu GA, Zanni MV, Neilan TG. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: Cardiooncology state-of-the-art review. JACC CardioOncol. 2022;4(5):598–615. https://doi.org/10.1016/j.jaccao.2022.11.011 .
doi: 10.1016/j.jaccao.2022.11.011
pubmed: 36636438
pmcid: 9830225
Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–68. https://doi.org/10.1093/cvr/cvz026 .
doi: 10.1093/cvr/cvz026
pubmed: 30715219
pmcid: 6452314
Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2019-000261
Titus A, Cheema HA, Shafiee A, et al. Statins for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis. Curr Probl Cardiol. 2023:101885. https://doi.org/10.1016/j.cpcardiol.2023.101885
Mahmood S, Fradley M, Cohen J, et al. Myocarditis in patients treated with immune checkpoint inhibitors. JACC. 2018;71(16):1755–64. https://doi.org/10.1016/j.jacc.2018.02.037 .
doi: 10.1016/j.jacc.2018.02.037
pubmed: 29567210
Dobbin SJH, Shen L, Petrie MC, et al. Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. Eur J Heart Fail. 2023;25(4):488–96. https://doi.org/10.1002/ejhf.2818 .
doi: 10.1002/ejhf.2818
pubmed: 36919816
Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10(8):559–67. https://doi.org/10.1016/j.jchf.2022.03.006 .
doi: 10.1016/j.jchf.2022.03.006
pubmed: 35902159
pmcid: 9638993
Abdel-Qadir H, Carrasco R, Austin PC, et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC: CardioOncol. 2023;5(3):318–28. https://doi.org/10.1016/j.jaccao.2023.03.011 .
doi: 10.1016/j.jaccao.2023.03.011
pubmed: 37397088
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925 .
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389 .
doi: 10.1056/NEJMoa1812389
pubmed: 30415602
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720 .
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997–1012. https://doi.org/10.1161/cir.0000000000000679 .
doi: 10.1161/cir.0000000000000679
pubmed: 30955352
pmcid: 7603804
Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136–45. https://doi.org/10.1016/j.semcancer.2020.06.005 .
doi: 10.1016/j.semcancer.2020.06.005
pubmed: 32544511
Porter C, Azam TU, Mohananey D, et al. Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC CardioOncol. 2022;4(3):302–12. https://doi.org/10.1016/j.jaccao.2022.07.005 .
doi: 10.1016/j.jaccao.2022.07.005
pubmed: 36213359
pmcid: 9537074
Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61–73. https://doi.org/10.1016/s0140-6736(18)32484-x .
doi: 10.1016/s0140-6736(18)32484-x
pubmed: 30429050
pmcid: 6319251